- MHRA touts uptick in approvals in 2025-2026 annual report<p>The UK's Medicines and Healthcare products Regulatory Agency (MHRA) touted its achievements over the last year its 2025-2026 annual report to Parliament, which includes approving more new drugs…raps · 7d ago↗ source
- Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s JournaxLatigo Biotherapeutics is preparing to go public in order to bankroll the development of its clinical-stage pipeline of non-opioid pain management drugs.Fierce Biotech · 8d ago↗ source
- Geopolitics ‘chills’ British biotech IPO plans, despite $2B in Q2 VC fundsGeopolitical uncertainty has continued to “chill” IPO sentiment among British biotechs, an industry leader has told Fierce, even as the sector saw second-quarter venture capital funding reach a fiv…